EXELIXIS INC (EXEL) Stock News
NASDAQ:EXEL - Nasdaq - US30161Q1040 - Common Stock - Currency: USD
EXEL Latest News, Press Relases and Analysis
Why EXELIXIS INC (NASDAQ:EXEL) is Poised for High Growth.
Exploring high growth characteristics of EXELIXIS INC (NASDAQ:EXEL). A fundamental and technical analysis of (NASDAQ:EXEL).
EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock and is consolidating.
Based on a technical and fundamental analysis of NASDAQ:EXEL we can say: EXELIXIS INC (NASDAQ:EXEL), a strong growth stock, setting up for a breakout.
Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires?
We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy according to billionaires. Why are Healthcare Stocks Under Pressure? Some experts view medical, healthcare, and big […]
Why Rocket Lab Stock Is Skyrocketing This Week
Shares of Rocket Lab (NASDAQ: RKLB) are trading higher this week. The launch service provider announced a new family of customizable satellite solar arrays at a major industry conference this week, boosting investor optimism. Rocket Lab announced its new Standardized Array (STARRAY) product line at the 40th Space Symposium in Colorado Springs.
For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering.
EXELIXIS INC was identified as a growth stock that isn't overvalued. NASDAQ:EXEL is excelling in various growth indicators while maintaining a solid financial footing.
EXELIXIS INC (NASDAQ:EXEL) stands out as a stock that provides good value for the fundamentals it showcases.
EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price.
Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?
We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is […]
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of 0% and 67.85%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Mentions: OBIO
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
Exelixis obtains FDA nod for label expansion of lead drug Cabometyx for neuroendocrine tumors.
Embattled Arbor hit with more investor “fraud” suits, rebuffs allegations
Arbor Realty Trust's Ivan Kaufman (YouTube/Ivan Kaufman, Getty)Amid a federal probe into its lending practices, Arbor Realty Trust now faces two more suits by investors alleging the REIT engaged in fraud by overstating its net income and abandoning its underwriting standards. The complaints, filed on Feb. 26 and March 17, make three cases total against the prolific lender to struggling […]This article originally appeared on The Real Deal. Click here to read the full story.
LandBridge price target raised to $88 from $73 at Goldman Sachs
Goldman Sachs raised the firm’s price target on LandBridge (LB) to $88 from $73 and keeps a Buy rating on the shares. The firm sees further upside for the company based on its disclosures in Q4 results regarding its revenue potential per acre as well as new third-party contracts, the analyst tells investors in a research note. The firm adds that its view remains that high operating leverage drives the value proposition for surface acreage with data centers, noting that its new price target is ba
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
Why Exelixis Stock Trounced the Market on Thursday
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week
From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.
